Key Points
- CEO Leon Moulder Jr. bought 25,000 shares on April 28 at $18.02 each ($450,500), increasing his direct stake to 1,751,039 shares (a 1.45% rise) now worth about $31.55M.
- The company is unprofitable (last quarter EPS -$1.10; analysts forecast -4.97 EPS for the year), trades with a negative P/E, has a market cap of roughly $1.01B, and the stock recently traded near $17.55 versus a 12‑month high of $44.60.
- Analyst coverage is mixed: the consensus rating is "Hold" with an average target price of $44.14, while individual ratings range from "strong sell" to "buy."
Zenas BioPharma, Inc. (NASDAQ:ZBIO - Get Free Report) CEO Leon Moulder, Jr. acquired 25,000 shares of Zenas BioPharma stock in a transaction on Tuesday, April 28th. The stock was purchased at an average price of $18.02 per share, with a total value of $450,500.00. Following the transaction, the chief executive officer directly owned 1,751,039 shares in the company, valued at approximately $31,553,722.78. This trade represents a 1.45% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Zenas BioPharma Price Performance
Shares of ZBIO stock opened at $17.55 on Thursday. The stock has a 50 day moving average of $22.48 and a two-hundred day moving average of $27.14. The company has a current ratio of 5.61, a quick ratio of 5.61 and a debt-to-equity ratio of 0.32. Zenas BioPharma, Inc. has a 12 month low of $8.51 and a 12 month high of $44.60. The company has a market capitalization of $1.01 billion, a P/E ratio of -2.25 and a beta of -0.54.
Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last announced its quarterly earnings data on Monday, April 13th. The company reported ($1.10) EPS for the quarter. As a group, equities analysts expect that Zenas BioPharma, Inc. will post -4.97 EPS for the current year.
Hedge Funds Weigh In On Zenas BioPharma
A number of hedge funds have recently modified their holdings of the stock. Quarry LP raised its holdings in shares of Zenas BioPharma by 34.5% in the 3rd quarter. Quarry LP now owns 1,134 shares of the company's stock worth $25,000 after buying an additional 291 shares in the last quarter. Deutsche Bank AG raised its holdings in shares of Zenas BioPharma by 4.5% in the 4th quarter. Deutsche Bank AG now owns 12,781 shares of the company's stock worth $464,000 after buying an additional 554 shares in the last quarter. CWM LLC boosted its holdings in shares of Zenas BioPharma by 48.3% in the 4th quarter. CWM LLC now owns 2,178 shares of the company's stock worth $79,000 after acquiring an additional 709 shares in the last quarter. Two Sigma Investments LP grew its position in Zenas BioPharma by 3.9% during the 3rd quarter. Two Sigma Investments LP now owns 20,382 shares of the company's stock worth $452,000 after acquiring an additional 765 shares during the last quarter. Finally, Bank of America Corp DE grew its position in Zenas BioPharma by 5.8% during the 3rd quarter. Bank of America Corp DE now owns 14,809 shares of the company's stock worth $329,000 after acquiring an additional 818 shares during the last quarter.
Analyst Upgrades and Downgrades
ZBIO has been the subject of a number of research reports. Zacks Research downgraded Zenas BioPharma from a "hold" rating to a "strong sell" rating in a research report on Tuesday, March 17th. Morgan Stanley increased their target price on Zenas BioPharma from $19.00 to $21.00 and gave the stock an "equal weight" rating in a report on Tuesday, March 17th. Guggenheim increased their target price on Zenas BioPharma from $45.00 to $55.00 and gave the stock a "buy" rating in a report on Monday, March 16th. Weiss Ratings reissued a "sell (d-)" rating on shares of Zenas BioPharma in a report on Friday, March 27th. Finally, Jefferies Financial Group reissued a "buy" rating and issued a $48.00 target price on shares of Zenas BioPharma in a report on Tuesday, January 6th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $44.14.
Check Out Our Latest Stock Analysis on ZBIO
About Zenas BioPharma
(
Get Free Report)
Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company's proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.
Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
